Walk us through briefly, please, through the decision to pursue high-grade glioma as your first indication, and what specific aspects of your stem cell-based delivery platform make it particularly promising for brain tumors where many other therapies have struggled?

We have seen great progress working with our partners at Northwestern University, Dr. Matt Lesniak, and at City of Hope, Dr. Karen Aboudi, Dr. Jana Portnow, around using these cell cell approaches, these stem cell loaded with an oncolytic virotherapy approach in treating these patients with high grade glioma.

And so dating back, I would say four years, Mark Foncannon- Four and five years ago as we were developing relationships with these MDS and PhDs at City of Hope at Northwestern University.

Mark Foncannon- They saw the collegiate super supernova technology was very much sister technology to what they were doing with with what we today call CLP one on one or neuro Nova and we were able to combine forces.

We exclusively licensed that technology and we've been able to bring to bear some of our manufacturing advantages to get much higher yield on the finished drug product.

And that means that we can treat patients at a much lower cost than was originally the plan and approach when it was just City of Hope and Northwestern University together.

So these are the types of benefits that we can bring where The years of work, nine and 10 years that Khalidi's team has been working on developing stem cells as a delivery platform, as that cloaking device or Trojan horse that protects from the immune system.

So obviously, Artenova data has been showcased at a variety, or will be as well going forward, a variety of conferences, the IOVC, ImmunoUS, and SITC presentations of that Artenova data, right? What has been the response so far that you've noticed from potential partners, key opinion leaders, particularly regarding the platform's ability to overcome historical challenges with systemic delivery of oncolytic viruses?